aibio
Company Updates ·
BioRestorative appoints Donald J. Currie to its board
The board appointed Donald J. Currie as a Class I director on October 7, 2026 to fill the seat left by Katharyn Field, and named him to two committees.
BRTX BioRestorative Therapies, Inc.
BioRestorative Therapies (BRTX) news BRTX reverse split and Nasdaq notice news
Latest BioRestorative Therapies news
- Company Updates
BioRestorative's R&D vice president resigns and claims severance
The company's board does not accept that the resignation was for good reason. The notice seeks about $1.29 million in cash severance under a disputed agreement.
- Listings
BioRestorative gets Nasdaq late-filing notice, then does a 1-for-20 reverse split
Nasdaq flagged a missing June-quarter 10-Q on Aug. 21. Days later the company announced a reverse split that cut its shares outstanding to about 1.38 million to fix a separate bid-price shortfall.
- Company Updates
BioRestorative suspends orders and shipments of two biocosmeceutical lines
The company paused its ExoCR and BioX products on August 7, 2026 while it reviews documentation, sourcing and regulatory status. It has not decided to discontinue them.
- Company Updates
BioRestorative's CEO and CFO resign and claim severance; a new CEO is named
Two executives gave notice on July 13, 2026 and asserted about $2.85 million in aggregate cash severance. The board does not accept the claims, and it named Katharyn Field chief executive officer.
- Debt Financing
BioRestorative sets up $1,000,000 revolving loan from Bowery Group
BioRestorative Therapies can borrow up to $1,000,000 from Bowery Group LLC at 12%, and the same agreement brought three director resignations and three new directors designated by the lender. Its cash use in 2025 was $10.8 million.
- Company Updates
BioRestorative files Lance Alstodt's employment agreement terms
The agreement, dated May 27, 2026, sets a three-year initial term and a bonus of up to 50% of salary. Severance equals two times salary plus bonus if he is terminated without cause or resigns for good reason.
What BioRestorative Therapies does
BioRestorative Therapies, Inc. develops therapeutic products using cell and tissue protocols, primarily involving adult stem cells. Its lead program is the Disc/Spine Program, whose initial investigational product, BRTX-100, is made from a patient's own cultured mesenchymal stem cells collected from bone marrow and injected into a damaged disc for the non-surgical treatment of painful lumbosacral disc disorders. BRTX-100 is in a Phase 2 clinical trial for chronic lower back pain from degenerative disc disease. The FDA cleared an IND for the product for chronic cervical discogenic pain, and granted Fast Track designation for chronic lumbar disc disease. The ThermoStem Program is a preclinical metabolic program using brown adipose derived stem cells and their exosomes to target obesity, type 2 diabetes and related disorders. The company also operates a commercial biocosmeceutical business whose cell-based secretome serum is engineered to reduce the appearance of fine lines and wrinkles. In February 2026 the company reported completing enrollment of 99 patients in its Phase 2 trial.
| Product or program | What it is | Stage |
|---|---|---|
| BRTX-100 | Patient-derived mesenchymal stem cell product injected into degenerative discs | Phase 2 trial for chronic lower back pain; IND cleared for cervical discogenic pain |
| ThermoStem Program | Brown adipose derived stem cells and exosomes for obesity and metabolic disorders | pre-clinical |
| Biocosmeceutical serum | Cell-based secretome serum for fine lines and wrinkles | commercial |
BioRestorative Therapies annual financials
| Line | FY2025 | FY2024 |
|---|---|---|
| Research and development | $10.1 million | $6.7 million |
| Net income (loss) | -$14.2 million | -$9.0 million |
| Cash from operations | -$10.8 million | -$8.2 million |
| Cash and equivalents | $1.5 million | $547,890 |
| Short-term investments | $1.4 million | $10.2 million |
Questions about BioRestorative Therapies
Did BioRestorative Therapies do a reverse stock split?
Our latest story on this, dated Sep 2, 2026: "BioRestorative gets Nasdaq late-filing notice, then does a 1-for-20 reverse split". The story links the filing or release it is based on. Read the story.
Has BioRestorative Therapies received a Nasdaq deficiency notice?
Our latest story on this, dated Sep 2, 2026: "BioRestorative gets Nasdaq late-filing notice, then does a 1-for-20 reverse split". The story links the filing or release it is based on. Read the story.
What is the ticker symbol of BioRestorative Therapies?
BioRestorative Therapies, Inc. trades under the ticker BRTX on NASDAQ.
Where is BioRestorative Therapies listed?
BioRestorative Therapies, Inc. is listed on NASDAQ.
What is the SEC CIK of BioRestorative Therapies?
The SEC Central Index Key (CIK) for BioRestorative Therapies, Inc. is 1505497. Its filings are on SEC EDGAR.
How many shares does BioRestorative Therapies have outstanding?
25,478,170 shares as of 2026-05-14, per the cover page of its 10-Q filed 2026-05-14.
Which country or territory is BioRestorative Therapies listed under?
Our directory records BioRestorative Therapies, Inc. under United States.
What does BioRestorative Therapies do?
Our directory classifies BioRestorative Therapies, Inc. as: Biopharma / pharmaceuticals. This is a directory classification, not a description of the pipeline.
What is the ISIN of BioRestorative Therapies?
The ISIN recorded for BioRestorative Therapies, Inc. is US0906557055.
Does aibio.space cover BioRestorative Therapies?
aibio.space lists BioRestorative Therapies, Inc. among 2,820 public biotech companies and publishes its news here as stories appear.
Where is BioRestorative Therapies incorporated?
SEC records list its state or country of incorporation as NV.
What does BioRestorative Therapies develop?
BioRestorative Therapies, Inc. develops therapeutic products using cell and tissue protocols, primarily involving adult stem cells. Its lead program is the Disc/Spine Program, whose initial investigational product, BRTX-100, is made from a patient's own cultured mesenchymal stem cells collected from bone marrow and injected into a damaged disc for the non-surgical treatment of painful lumbosacral disc disorders.
What is BRTX-100 from BioRestorative Therapies?
BRTX-100: Patient-derived mesenchymal stem cell product injected into degenerative discs Stage: Phase 2 trial for chronic lower back pain; IND cleared for cervical discogenic pain.
What is ThermoStem Program from BioRestorative Therapies?
ThermoStem Program: Brown adipose derived stem cells and exosomes for obesity and metabolic disorders Stage: pre-clinical.
Is BioRestorative Therapies profitable?
BioRestorative Therapies, Inc. reported a net loss of $14.2 million for the fiscal year ended Dec 31, 2025, and used $10.8 million of cash in operations, per its annual report to the SEC.
Investor discussion: BioRestorative Therapies
Rules
- Securities violations are strictly forbidden. No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information.
- Say whether you hold the stock. Every post states long, short or no position.
- No paid or sponsored posts. Do not post for anyone who pays or rewards you.
- No buy or sell calls and no price targets.
- No accusations of crime or fraud against named people unless you link a court filing or a regulator's release that makes them.
- No personal details and no spam. No links at all for your first 7 days as a member.
Capital-markets timeline
- Legal
Reported a change of independent auditor. SEC Form 8-K (Items 4.01,5.02,9.01). Source
- Listings
Reported a reverse stock split. SEC Form 8-K (Items 3.03,5.03,7.01,9.01). Source
- Listings
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01,9.01). Source
- Distress
Told the SEC a periodic report would be filed late. SEC Form NT 10-Q. Source
- Listings
Reported a shareholder vote on a reverse stock split or more authorized shares. SEC Form 8-K (Items 5.02,5.07,9.01). Source
- Financings
Reported a financing. SEC Form S-1. Source
- Financings
Filed a registration statement for a share offering. SEC Form S-1. Source
- Legal
Reported a change of independent auditor. SEC Form 8-K (Items 4.01,9.01). Source
- Distress
Reported substantial doubt about its ability to continue as a going concern. SEC Form 10-K. Source
Stock chart
SEC filings and registration
- SEC name
- BioRestorative Therapies, Inc.
- CIK
- 1505497
- Industry (SIC)
- Services-Misc Health & Allied Services, NEC (8090)
- US tickers
- BRTX (Nasdaq)
- State or country of incorporation
- NV
- Fiscal year ends
- December 31
- Filer category
- Non-accelerated filer<br>Smaller reporting company
- Business address
- 40 MARCUS DRIVE, MELVILLE, NY
- Phone
- (631) 760-8100
- Shares outstanding
- 25,478,170 as of 2026-05-14 (10-Q filed 2026-05-14)
- Former names
- Stem Cell Assurance, Inc.
Recent filings
Listing details
- Company
- BioRestorative Therapies, Inc.
- Ticker
- BRTX
- Listing
- NASDAQ
- Country or territory
- United States
- Business scope
- Biopharma / pharmaceuticals
- ISIN
- US0906557055
- Last quote in directory
- 2026-10-21
- Directory source
- Listing page
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction